<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="letter"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur Respir J</journal-id><journal-id journal-id-type="iso-abbrev">Eur. Respir. J</journal-id><journal-id journal-id-type="publisher-id">erj</journal-id><journal-title-group><journal-title>The European Respiratory Journal</journal-title></journal-title-group><issn pub-type="ppub">0903-1936</issn><issn pub-type="epub">1399-3003</issn><publisher><publisher-name>European Respiratory Society</publisher-name><publisher-loc>442 Glossop Road, Sheffield, S10 2PX, UK</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24036246</article-id><article-id pub-id-type="pmc">3814414</article-id><article-id pub-id-type="publisher-id">erj00939-2013</article-id><article-id pub-id-type="doi">10.1183/09031936.00093913</article-id><article-categories><subj-group subj-group-type="heading"><subject>Letters</subject></subj-group><subj-group subj-group-type="hwp-journal-coll"><subject>2</subject><subject>1</subject></subj-group></article-categories><title-group><article-title>Randomised controlled trial of azithromycin in smokers with asthma</article-title><alt-title alt-title-type="short">RCTs of azithromycin in smokers with asthma</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Cameron</surname><given-names>Euan J.</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Chaudhuri</surname><given-names>Rekha</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Mair</surname><given-names>Frances</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>McSharry</surname><given-names>Charles</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Greenlaw</surname><given-names>Nicola</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Weir</surname><given-names>Christopher J.</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Jolly</surname><given-names>Lisa</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Donnelly</surname><given-names>Iona</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Gallacher</surname><given-names>Katie</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Morrison</surname><given-names>Deborah</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Spears</surname><given-names>Mark</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Evans</surname><given-names>Tom J.</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Anderson</surname><given-names>Kenneth</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Thomson</surname><given-names>Neil C.</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1"/></contrib></contrib-group><aff id="aff1"><label>1</label><institution>Institute of Infection, Immunity and Inflammation, University of Glasgow</institution>, <addr-line>Glasgow</addr-line></aff><aff id="aff2"><label>2</label><institution>General Practice and Primary Care, Institute of Health and Wellbeing, University of Glasgow</institution>, <addr-line>Glasgow</addr-line></aff><aff id="aff3"><label>3</label><institution>Robertson Centre for Biostatistics, University of Glasgow</institution>, <addr-line>Glasgow</addr-line></aff><aff id="aff4"><label>4</label><institution>Respiratory Medicine, Crosshouse Hospital</institution>, <addr-line>Kilmarnock</addr-line>, <country>UK</country></aff><author-notes><corresp id="cor1">N.C. Thomson, Institute of Infection, Immunity and Inflammation, University of Glasgow, Sir Graeme Davies Building, 120 University Place, Glasgow, G12 8TA, UK. E-mail: <email>neil.thomson@glasgow.ac.uk</email></corresp></author-notes><pub-date pub-type="ppub"><month>11</month><year>2013</year></pub-date><volume>42</volume><issue>5</issue><fpage>1412</fpage><lpage>1415</lpage><history><date date-type="received"><day>03</day><month>6</month><year>2013</year></date><date date-type="accepted"><day>10</day><month>7</month><year>2013</year></date></history><permissions><copyright-statement>&#x000a9;ERS 2013</copyright-statement><copyright-year>2013</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/"><license-p>ERJ Open articles are open access and distributed under the terms of the (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">Creative Commons Attribution Licence 3.0&#x0003e;</ext-link>)</license-p></license></permissions></article-meta></front><body><p>To the Editor:</p><p>Smokers with asthma have poor symptom control, accelerated decline in lung function and an attenuated response to corticosteroids compared to nonsmokers with asthma [<xref ref-type="bibr" rid="b1">1</xref>]. There is an unmet need for alternative or additional drugs for smokers with asthma who are unable to stop smoking [<xref ref-type="bibr" rid="b2">2</xref>]. Macrolide antibiotics have anti-inflammatory activity [<xref ref-type="bibr" rid="b3">3</xref>] and in clinical studies there is good evidence for efficacy in the treatment of diffuse pan-bronchiolitis and cystic fibrosis, as well as in preventing chronic rejection after lung transplantation [<xref ref-type="bibr" rid="b4">4</xref>, <xref ref-type="bibr" rid="b5">5</xref>]. In asthma, chronic treatment is associated with a reduction in bronchial hyperreactivity in mild-to-moderate asthma [<xref ref-type="bibr" rid="b6">6</xref>] and in exacerbation rates in non-eosinophilic severe asthma [<xref ref-type="bibr" rid="b7">7</xref>]. To date, no studies have examined the efficacy of macrolide antibiotics exclusively in current smokers with asthma.</p><p>A randomised double-blind parallel-group trial compared azithromycin, 250 mg per day, with placebo for 12 weeks. All subjects were aged 18&#x02013;70 years, were current smokers (&#x02265;5 pack-years history) with chronic asthma (&#x0003e;1 year duration; defined by international criteria [<xref ref-type="bibr" rid="b8">8</xref>]) and had to be free of exacerbation and respiratory tract infection for a minimum 6-week period prior to randomisation. A baseline visit was performed following a 4-week run-in period on inhaled corticosteroid (ICS) therapy equivalent to 400 &#x003bc;g beclometasone &#x000b1; a long-acting &#x003b2;<sub>2</sub>-agonist (LABA). Ethical approval was obtained and all subjects provided written informed consent. Study visits were performed at 4, 8 and 12 weeks. Clinic visit peak expiratory flow (PEF) after 12 weeks treatment was the primary outcome measure. A sample size of 68 was calculated to have an 80% power to detect a mean difference of 25 L&#x000b7;min<sup>&#x02212;1</sup> in change from baseline to 12 weeks in morning PEF, the primary end-point [<xref ref-type="bibr" rid="b9">9</xref>], assuming a standard deviation of changes of 36 L&#x000b7;min<sup>&#x02212;1</sup> using a two-sample t-test with a 5% two-sided significance level. Recruitment of 80 patients was planned to ensure that 68 patients completed the study. 77 subjects were randomised with 71 completing the study. Other measures of airway responsiveness PC<sub>20</sub> (provocation concentration of methacholine causing a 20% fall in forced expiratory volume in 1 s (FEV<sub>1</sub>)), inflammation (exhaled nitric oxide fraction at 50 mL&#x000b7;s<sup>&#x02212;1</sup> (<italic>F</italic><sub>eNO50</sub>)/induced sputum/blood and sputum supernatant biomarkers), symptom control (Asthma Control Questionnaire (ACQ) [<xref ref-type="bibr" rid="b10">10</xref>] and Leicester Cough Questionnaire (LCQ) [<xref ref-type="bibr" rid="b11">11</xref>]) and quality of life (Asthma Quality of Life Questionnaire (AQLQ) [<xref ref-type="bibr" rid="b10">10</xref>]) were assessed during the study. PEF was recorded using Piko-1 electronic peak flow meters (nSpire, Hertford, UK) and symptoms were recorded in a validated diary card [<xref ref-type="bibr" rid="b10">10</xref>]. Bacteriological and virological analysis of induced sputum was also undertaken. All statistical tests were two-sided and used a significance level of 5%. All data was analysed using SAS (version 9.2; SAS Institute, Cary, NC, USA). QTc was also measured at baseline and 12 weeks.</p><p>Baseline demographic data and clinical characteristics of the patients were comparable and the two groups were well balanced. Placebo <italic>versus</italic> azithromycin groups: age 42.8&#x000b1;9.4 years <italic>versus</italic> 46.4&#x000b1;8.8 years; male sex 17 (44.7%) <italic>versus</italic> 20 (51.3%); smoking history 23.6&#x000b1;15.8 pack-years <italic>versus</italic> 28.6&#x000b1;16.4 pack-years; duration of asthma 24.6&#x000b1;12.6 years <italic>versus</italic> 18.8&#x000b1;12.5 years; atopic 23 (60.1%) <italic>versus</italic> 27 (69.2%); median (interquartile range) total IgE 103 (38&#x02013;291) IU&#x000b7;mL<sup>&#x02212;1</sup>
<italic>versus</italic> 165 (48&#x02013;254) IU&#x000b7;mL<sup>&#x02212;1</sup>; use of ICS at screening 31 (81.6%) <italic>versus</italic> 35 (89.7%); equivalent beclomethasone dose at screening 709&#x000b1;564 &#x003bc;g <italic>versus</italic> 603&#x000b1;457 &#x003bc;g; use of LABA at randomisation 18 (47.4%) <italic>versus</italic> 15 (38.5%); pre-bronchodilator FEV<sub>1</sub> 81.0&#x000b1;16.8% predicted <italic>versus</italic> 78.3&#x000b1;16.4% pred; post-bronchodilator FEV<sub>1</sub> 89.0&#x000b1;15.1% pred <italic>versus</italic> 86.8&#x000b1;15.2% pred; FEV<sub>1</sub> 11.3&#x000b1;9.8% reversibility<italic> versus</italic> 12.3&#x000b1;10% reversibility; geometric mean PC<sub>20</sub> 1.06&#x000b1;4.10 mg&#x000b7;mL<sup>&#x02212;1</sup><italic> versus</italic> 1.07&#x000b1;3.13 mg&#x000b7;mL<sup>&#x02212;1</sup>.</p><p>At the final study visit (12 weeks) the change in mean morning clinic PEF (primary outcome), as compared with baseline, did not differ substantially between the azithromycin and placebo treatment groups (mean difference -10.3 (95% CI 47.1&#x02013;26.4 L&#x000b7;min<sup>&#x02212;1</sup>), p=0.58) (<xref ref-type="table" rid="erj-42-05-1412-t01">table 1</xref>). There was no difference in either pre- or post-albuterol FEV<sub>1</sub> at 4, 8 or 12 weeks between the two groups (<xref ref-type="table" rid="erj-42-05-1412-t01">table 1</xref>). No differences were evident for PC<sub>20</sub> (baseline to 12 week comparison) between the azithromycin or placebo groups (<xref ref-type="table" rid="erj-42-05-1412-t01">table 1</xref>). None of the self-reported diary card recordings (ACQ, AQLQ or LCQ score) demonstrated any significant differences between the two groups at 4, 8 or 12 weeks. Noninvasive measures of inflammation, <italic>i.e.</italic> induced sputum, sputum supernatant cytokines, peripheral blood cytokines and <italic>F</italic><sub>eNO50</sub>, did not demonstrate any substantial improvements after 12-weeks of treatment with azithromycin (<xref ref-type="table" rid="erj-42-05-1412-t01">table 1</xref>). Bacterial colony counts did not demonstrate any treatment difference between the placebo and azithromycin groups (p=0.66, data not shown). PCR for <italic>Mycoplasma pneumonia</italic> and <italic>Chlamydophila pneumoniae</italic> were negative at both baseline and 12 weeks. QTc was unchanged following 12 weeks of treatment with azithromycin.</p><table-wrap id="erj-42-05-1412-t01" position="float"><label>Table 1&#x02013;</label><caption><title>Clinical outcomes and sputum cell counts after azithromycin treatment or placebo</title></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"><bold>Variables</bold></td><td colspan="2" align="center" rowspan="1"><bold>Baseline</bold></td><td colspan="2" align="center" rowspan="1"><bold>4 weeks</bold></td><td align="center" rowspan="1" colspan="1"><bold>Treatment difference<sup>#</sup>, azithromycin minus placebo (95%CI)</bold></td><td colspan="2" align="center" rowspan="1"><bold>8 weeks</bold></td><td align="center" rowspan="1" colspan="1"><bold>Treatment difference<sup>#</sup>, azithromycin minus placebo (95%CI)</bold></td><td colspan="2" align="center" rowspan="1"><bold>12 weeks</bold></td><td align="center" rowspan="1" colspan="1"><bold>Treatment difference<sup>#</sup>, azithromycin minus placebo (95%CI)</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"><bold>Placebo</bold></td><td align="center" rowspan="1" colspan="1"><bold>Azithromycin</bold></td><td align="center" rowspan="1" colspan="1"><bold>Placebo</bold></td><td align="center" rowspan="1" colspan="1"><bold>Azithromycin</bold></td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"><bold>Placebo</bold></td><td align="center" rowspan="1" colspan="1"><bold>Azithromycin</bold></td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"><bold>Placebo</bold></td><td align="center" rowspan="1" colspan="1"><bold>Azithromycin</bold></td><td align="left" rowspan="1" colspan="1"/></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>Morning clinic PEF L&#x000b7;min<sup>&#x02212;1</sup></bold></td><td align="center" rowspan="1" colspan="1">411.1&#x000b1;124.3</td><td align="center" rowspan="1" colspan="1">390.5&#x000b1;114.5</td><td align="center" rowspan="1" colspan="1">412.9&#x000b1;110.6</td><td align="center" rowspan="1" colspan="1">384.2&#x000b1;143.5</td><td align="center" rowspan="1" colspan="1">-4.2 (-30.6&#x02013;22.2), p=0.75</td><td align="center" rowspan="1" colspan="1">406.0&#x000b1;120.4</td><td align="center" rowspan="1" colspan="1">394.6&#x000b1;150.7</td><td align="center" rowspan="1" colspan="1">1.2 (-28.1&#x02013;30.5), p=0.94</td><td align="center" rowspan="1" colspan="1">416.7&#x000b1;122.7</td><td align="center" rowspan="1" colspan="1">394.2&#x000b1;156.3</td><td align="center" rowspan="1" colspan="1">-10.3 (-47.1&#x02013;26.4), p=0.58</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>FEV<sub>1</sub> pre-albuterol L</bold></td><td align="center" rowspan="1" colspan="1">2.54&#x000b1;0.77</td><td align="center" rowspan="1" colspan="1">2.43&#x000b1;0.72</td><td align="center" rowspan="1" colspan="1">2.48&#x000b1;0.74</td><td align="center" rowspan="1" colspan="1">2.37&#x000b1;0.76</td><td align="center" rowspan="1" colspan="1">0.08 (-0.06&#x02013;0.23), p=0.25</td><td align="center" rowspan="1" colspan="1">2.47&#x000b1;0.77</td><td align="center" rowspan="1" colspan="1">2.42&#x000b1;0.75</td><td align="center" rowspan="1" colspan="1">0.03 (-0.08&#x02013;0.14), p=0.55</td><td align="center" rowspan="1" colspan="1">2.46&#x000b1;0.75</td><td align="center" rowspan="1" colspan="1">2.41&#x000b1;0.77</td><td align="center" rowspan="1" colspan="1">0.03 (-0.08&#x02013;0.14), p=0.62</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>FEV<sub>1</sub> post-albuterol L</bold></td><td align="center" rowspan="1" colspan="1">2.80&#x000b1;0.80</td><td align="center" rowspan="1" colspan="1">2.68&#x000b1;0.73</td><td align="center" rowspan="1" colspan="1">2.73&#x000b1;0.72</td><td align="center" rowspan="1" colspan="1">2.59&#x000b1;0.74</td><td align="center" rowspan="1" colspan="1">0.04 (-0.08&#x02013;0.17), p=0.50</td><td align="center" rowspan="1" colspan="1">2.72&#x000b1;0.80</td><td align="center" rowspan="1" colspan="1">2.68&#x000b1;0.74</td><td align="center" rowspan="1" colspan="1">0.04 (-0.04&#x02013;0.12), p=0.34</td><td align="center" rowspan="1" colspan="1">2.70&#x000b1;0.79</td><td align="center" rowspan="1" colspan="1">2.66&#x000b1;0.77</td><td align="center" rowspan="1" colspan="1">0.04 (-0.06&#x02013;0.14), p=0.41</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Reliever inhaler puffs per 24 h</bold></td><td align="center" rowspan="1" colspan="1">2.8&#x000b1;2.9</td><td align="center" rowspan="1" colspan="1">2.9&#x000b1;4.4</td><td align="center" rowspan="1" colspan="1">2.5&#x000b1;2.7</td><td align="center" rowspan="1" colspan="1">3.1&#x000b1;4.4</td><td align="center" rowspan="1" colspan="1">-0.1 (-0.8&#x02013;0.6), p=0.78</td><td align="center" rowspan="1" colspan="1">2.5&#x000b1;2.6</td><td align="center" rowspan="1" colspan="1">2.4&#x000b1;2.8</td><td align="center" rowspan="1" colspan="1">0.3 (-0.5&#x02013;1.0), p=0.50</td><td align="center" rowspan="1" colspan="1">2.7&#x000b1;2.5</td><td align="center" rowspan="1" colspan="1">3.0 [4.0</td><td align="center" rowspan="1" colspan="1">-0.3 (-1.3&#x02013;0.7), p=0.55</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>7-point ACQ score</bold></td><td align="center" rowspan="1" colspan="1">1.76&#x000b1;0.88</td><td align="center" rowspan="1" colspan="1">1.73&#x000b1;0.74</td><td align="center" rowspan="1" colspan="1">1.64&#x000b1;0.90</td><td align="center" rowspan="1" colspan="1">1.74&#x000b1;0.85</td><td align="center" rowspan="1" colspan="1">0.12 (-0.18&#x02013;0.42), p=0.43</td><td align="center" rowspan="1" colspan="1">1.69 &#x000b1;1.03</td><td align="center" rowspan="1" colspan="1">1.86&#x000b1;0.99</td><td align="center" rowspan="1" colspan="1">0.21 (-0.14&#x02013;0.55), p=0.23</td><td align="center" rowspan="1" colspan="1">1.58&#x000b1;0.96</td><td align="center" rowspan="1" colspan="1">1.75&#x000b1;0.83</td><td align="center" rowspan="1" colspan="1">0.21 (-0.11&#x02013;0.53), p=0.20</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>logPC<sub>20</sub> mg&#x000b7;mL<sup>&#x02212;1</sup></bold></td><td align="center" rowspan="1" colspan="1">0.07&#x000b1;1.14</td><td align="center" rowspan="1" colspan="1">0.06&#x000b1;1.41</td><td align="center" rowspan="1" colspan="1">ND</td><td align="center" rowspan="1" colspan="1">ND</td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">ND</td><td align="center" rowspan="1" colspan="1">ND</td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.19&#x000b1;1.29</td><td align="center" rowspan="1" colspan="1">0.20&#x000b1;1.52</td><td align="center" rowspan="1" colspan="1">-0.02 (-0.49&#x02013;0.45), p=0.93</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Total LCQ score</bold></td><td align="center" rowspan="1" colspan="1">16.90&#x000b1;3.49</td><td align="center" rowspan="1" colspan="1">16.31&#x000b1;3.53</td><td align="center" rowspan="1" colspan="1">ND</td><td align="center" rowspan="1" colspan="1">ND</td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">ND</td><td align="center" rowspan="1" colspan="1">ND</td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">17.51&#x000b1;3.55</td><td align="center" rowspan="1" colspan="1">16.01&#x000b1;3.02</td><td align="center" rowspan="1" colspan="1">-1.06 (-2.16&#x02013;0.05), p=0.06</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Total AQLQ score</bold></td><td align="center" rowspan="1" colspan="1">5.09&#x000b1;0.99</td><td align="center" rowspan="1" colspan="1">5.25&#x000b1;1.18</td><td align="center" rowspan="1" colspan="1">ND</td><td align="center" rowspan="1" colspan="1">ND</td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">ND</td><td align="center" rowspan="1" colspan="1">ND</td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">5.42&#x000b1;1.31</td><td align="center" rowspan="1" colspan="1">5.20&#x000b1;1.06</td><td align="center" rowspan="1" colspan="1">-0.31 (-0.69&#x02013;0.07), p=0.11</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold><italic>F</italic><sub>eNO50</sub> ppb</bold></td><td align="center" rowspan="1" colspan="1">15.6&#x000b1;21.2</td><td align="center" rowspan="1" colspan="1">11.5&#x000b1;8.9</td><td align="center" rowspan="1" colspan="1">ND</td><td align="center" rowspan="1" colspan="1">ND</td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">ND</td><td align="center" rowspan="1" colspan="1">ND</td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">16.2&#x000b1;20.1</td><td align="center" rowspan="1" colspan="1">11.0&#x000b1;7.9</td><td align="center" rowspan="1" colspan="1">-1.94 (-5.97&#x02013;2.10), p=0.34</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Total sputum cell count &#x000d7;10<sup>4</sup></bold></td><td align="center" rowspan="1" colspan="1">644&#x000b1;240</td><td align="center" rowspan="1" colspan="1">626&#x000b1;245</td><td align="center" rowspan="1" colspan="1">ND</td><td align="center" rowspan="1" colspan="1">ND</td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">ND</td><td align="center" rowspan="1" colspan="1">ND</td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">714&#x000b1;326</td><td align="center" rowspan="1" colspan="1">668&#x000b1;211</td><td align="center" rowspan="1" colspan="1">1.0 (0.9&#x02013;1.2), p=0.75</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Neutrophil &#x000d7;10<sup>4</sup></bold></td><td align="center" rowspan="1" colspan="1">150&#x000b1;123</td><td align="center" rowspan="1" colspan="1">172&#x000b1;103</td><td align="center" rowspan="1" colspan="1">ND</td><td align="center" rowspan="1" colspan="1">ND</td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">ND</td><td align="center" rowspan="1" colspan="1">ND</td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">141&#x000b1;96</td><td align="center" rowspan="1" colspan="1">162&#x000b1;97</td><td align="center" rowspan="1" colspan="1">19.2 (-24.2&#x02013;62.6), p=0.38</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Neutrophil %</bold></td><td align="center" rowspan="1" colspan="1">33.1&#x000b1;24.3</td><td align="center" rowspan="1" colspan="1">39.0&#x000b1;22.5</td><td align="center" rowspan="1" colspan="1">ND</td><td align="center" rowspan="1" colspan="1">ND</td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">ND</td><td align="center" rowspan="1" colspan="1">ND</td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">31.0&#x000b1;19.9</td><td align="center" rowspan="1" colspan="1">34.4&#x000b1;18.6</td><td align="center" rowspan="1" colspan="1">3.0 (-5.9&#x02013;11.8), p=0.50</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Eosinophil &#x000d7;10<sup>4</sup></bold></td><td align="center" rowspan="1" colspan="1">4.9&#x000b1;6.4</td><td align="center" rowspan="1" colspan="1">6.9&#x000b1;9.3</td><td align="center" rowspan="1" colspan="1">ND</td><td align="center" rowspan="1" colspan="1">ND</td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">ND</td><td align="center" rowspan="1" colspan="1">ND</td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">6.8&#x000b1;13.9</td><td align="center" rowspan="1" colspan="1">10.3&#x000b1;20.1</td><td align="center" rowspan="1" colspan="1">1.0 (0.5&#x02013;2.0), p=0.89</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Eosinophil %</bold></td><td align="center" rowspan="1" colspan="1">1.1&#x000b1;1.5</td><td align="center" rowspan="1" colspan="1">1.6&#x000b1;2.3</td><td align="center" rowspan="1" colspan="1">ND</td><td align="center" rowspan="1" colspan="1">ND</td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">ND</td><td align="center" rowspan="1" colspan="1">ND</td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1.5&#x000b1;3.1</td><td align="center" rowspan="1" colspan="1">1.6&#x000b1;3.0</td><td align="center" rowspan="1" colspan="1">-0.4 (-1.8&#x02013;1.0), p=0.55</td></tr></tbody></table><table-wrap-foot><fn id="nt101"><p>Data are presented as mean&#x000b1;<sc>sd,</sc> unless otherwise stated. PEF: peak expiratory flow rate; FEV<sub>1</sub>: forced expiratory volume in 1 s; ACQ: Asthma Control Questionnaire; PC<sub>20</sub>: provocation concentration of methacholine causing a 20% fall in FEV<sub>1</sub>; LCQ: Leicester Cough Questionnaire; AQLQ: Asthma Quality of Life Questionnaire; <italic>F</italic><sub>eNO50</sub>: exhaled nitric oxide fraction at 50 mL&#x000b7;s<sup>&#x02212;1</sup>; ND: not done. <sup>#</sup>: treatment difference from ANCOVA analysing change from baseline and adjusting for baseline value.</p></fn></table-wrap-foot></table-wrap><p>No suspected unexpected serious adverse events occurred during the reporting period of the study. Compliance assessed by capsule count was &#x0003e;90% in each group.</p><p>In the first randomised controlled study of azithromycin in smokers with asthma we found that there were no clinically important improvements in both the primary end-point and morning PEF, and in a range of secondary clinical outcomes including ACQ score, AQLQ score, spirometry and airway responsiveness, as well as measures of airway inflammation after 12 weeks of treatment. The median ACQ score of the participants recruited to the study was raised at 1.7 indicating that they had poorly controlled disease and scope for clinical improvement. We believe that the choice of a different macrolide from azithromycin or a different dose of azithromycin is unlikely to have altered our findings. This study was powered to test the hypothesis on the primary end-point, PEF. We exceeded our minimum recruitment target ensuring adequate numbers completed the study. The lack of response to treatment was such that recruiting greater numbers would be unlikely to affect either the primary end-point or the majority of secondary analyses. Taken together these findings indicate that short-term therapy with azithromycin does not improve lung function or other indices of current asthma control of smokers with mild-to-moderate asthma who are already receiving treatment with inhaled corticosteroids. This is supported by a recent study where 6 months of treatment with azithromycin in nonsmokers with severe asthma did not improve lung function [<xref ref-type="bibr" rid="b7">7</xref>].</p><p>Recently published data reported that azithromycin administered over 1 year reduced the rate of exacerbations in chronic obstructive pulmonary disease (COPD), although this benefit was not found in current smokers with COPD, and bronchiectasis was not an exclusion [<xref ref-type="bibr" rid="b12">12</xref>, <xref ref-type="bibr" rid="b13">13</xref>]. Moreover, a 6-month study with azithromycin in nonsmokers with severe asthma powered to measure exacerbation frequency did not find any statistical difference between treatment and placebo groups [<xref ref-type="bibr" rid="b7">7</xref>], although a beneficial effect of azithromycin on reducing exacerbations was reported in patients with non-eosinophilic asthma [<xref ref-type="bibr" rid="b7">7</xref>]. The smokers with asthma in our study had non-eosinophilic asthma, but did not respond to azithromycin, although the duration of treatment was not long enough to assess the effects of azithromycin on exacerbations.</p><p>In conclusion, we have studied the effects of 12 weeks of azithromycin in smokers with asthma, an understudied patient group, and provide clear evidence demonstrating lack of efficacy in both clinical and laboratory outcomes. Further randomised clinical trials exploring new therapies in smokers with asthma who are unable to stop smoking are required.</p></body><back><fn-group><fn fn-type="financial-disclosure"><p>Support statement: This work was funded by the <funding-source>Medical Research Council UK</funding-source> and supported financially by <funding-source>NHS Research Scotland</funding-source> (NRS), through the Scottish Primary Care Research Network; study medication (budesonide Easyhalers; Orion Pharma (UK), Newbury, UK) was purchased with an educational grant from <funding-source>AstraZeneca</funding-source> (London, UK).</p></fn><fn fn-type="supplementary-material"><p>Clinical trial: This study is registered at <ext-link ext-link-type="uri" xlink:href="www.Clinicaltrials.gov">www.Clinicaltrials.gov</ext-link> with identifier number NCT00852579.</p></fn><fn fn-type="conflict"><p>Conflict of interest: Disclosures can be found alongside the online version of this article at <ext-link ext-link-type="uri" xlink:href="www.erj.ersjournals.com">www.erj.ersjournals.com</ext-link></p></fn></fn-group><ref-list><title>References</title><ref id="b1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomson</surname><given-names>N</given-names></name><name><surname>Chaudhuri</surname><given-names>R</given-names></name></person-group>
<article-title>Asthma in smokers: challenges and opportunities</article-title>. <source>Curr Opin Pulm Med</source>
<year>2009</year>; <volume>15</volume>: <fpage>39</fpage>&#x02013;<lpage>45</lpage><pub-id pub-id-type="pmid">19077704</pub-id></mixed-citation></ref><ref id="b2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Polosa</surname><given-names>R</given-names></name><name><surname>Thomson</surname><given-names>NC</given-names></name></person-group>
<article-title>Smoking and asthma: dangerous liaisons</article-title>. <source>Eur Respir J</source>
<year>2013</year>; <volume>41</volume>: <fpage>716</fpage>&#x02013;<lpage>726</lpage><pub-id pub-id-type="pmid">22903959</pub-id></mixed-citation></ref><ref id="b3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cameron</surname><given-names>EJ</given-names></name><name><surname>McSharry</surname><given-names>C</given-names></name><name><surname>Chaudhuri</surname><given-names>R</given-names></name><etal/></person-group>
<article-title>Long-term macrolide treatment of chronic inflammatory airway diseases: risks, benefits and future developments</article-title>. <source>Clin Exp Allergy</source>
<year>2012</year>; <volume>42</volume>: <fpage>1302</fpage>&#x02013;<lpage>1312</lpage><pub-id pub-id-type="pmid">22925316</pub-id></mixed-citation></ref><ref id="b4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spagnolo</surname><given-names>P</given-names></name><name><surname>Fabbri</surname><given-names>LM</given-names></name><name><surname>Bush</surname><given-names>A</given-names></name></person-group>
<article-title>Long-term macrolide treatment for chronic respiratory disease</article-title>. <source>Eur Respir J</source>
<year>2013</year>; <volume>42</volume>: <fpage>239</fpage>&#x02013;<lpage>251</lpage><pub-id pub-id-type="pmid">23180583</pub-id></mixed-citation></ref><ref id="b5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vos</surname><given-names>R</given-names></name><name><surname>Vanaudenaerde</surname><given-names>BM</given-names></name><name><surname>Verleden</surname><given-names>SE</given-names></name><etal/></person-group>
<article-title>A randomised controlled trial of azithromycin to prevent chronic rejection after lung transplantation</article-title>. <source>Eur Respir J</source>
<year>2011</year>; <volume>37</volume>: <fpage>164</fpage>&#x02013;<lpage>172</lpage><pub-id pub-id-type="pmid">20562124</pub-id></mixed-citation></ref><ref id="b6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sutherland</surname><given-names>ER</given-names></name><name><surname>King</surname><given-names>TS</given-names></name><name><surname>Icitovic</surname><given-names>N</given-names></name><etal/></person-group>
<article-title>A trial of clarithromycin for the treatment of suboptimally controlled asthma</article-title>. <source>J Allergy Clin Immunol</source>
<year>2010</year>; <volume>126</volume>: <fpage>747</fpage>&#x02013;<lpage>753</lpage><pub-id pub-id-type="pmid">20920764</pub-id></mixed-citation></ref><ref id="b7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brusselle</surname><given-names>GG</given-names></name><name><surname>Vanderstichele</surname><given-names>C</given-names></name><name><surname>Jordens</surname><given-names>P</given-names></name><etal/></person-group>
<article-title>Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial</article-title>. <source>Thorax</source>
<year>2013</year>; <volume>68</volume>: <fpage>322</fpage>&#x02013;<lpage>329</lpage><pub-id pub-id-type="pmid">23291349</pub-id></mixed-citation></ref><ref id="b8"><label>8</label><mixed-citation publication-type="book"><collab>Global Initiative for Asthma</collab>
<article-title>Global Strategy for Asthma Management and Prevention</article-title>. <publisher-name>GINA</publisher-name>, <year>2010</year>
<comment><ext-link ext-link-type="uri" xlink:href="www.ginasthma.org">www.ginasthma.org</ext-link></comment></mixed-citation></ref><ref id="b9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greening</surname><given-names>A</given-names></name><name><surname>Ind</surname><given-names>P</given-names></name><name><surname>Northfield</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Added salmeterol <italic>versus</italic> higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid</article-title>. <source>Lancet</source>
<year>1994</year>; <volume>344</volume>: <fpage>219</fpage>&#x02013;<lpage>224</lpage><pub-id pub-id-type="pmid">7913155</pub-id></mixed-citation></ref><ref id="b10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reddel</surname><given-names>HK</given-names></name><name><surname>Taylor</surname><given-names>DR</given-names></name><name><surname>Bateman</surname><given-names>ED</given-names></name><etal/></person-group>
<article-title>An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice</article-title>. <source>Am J Respir Crit Care Med</source>
<year>2009</year>; <volume>180</volume>: <fpage>59</fpage>&#x02013;<lpage>99</lpage><pub-id pub-id-type="pmid">19535666</pub-id></mixed-citation></ref><ref id="b11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Birring</surname><given-names>SS</given-names></name><name><surname>Prudon</surname><given-names>B</given-names></name><name><surname>Carr</surname><given-names>AJ</given-names></name><etal/></person-group>
<article-title>Development of a symptom specific health status measure for patients with chronic cough: Leicester Cough Questionnaire (LCQ)</article-title>. <source>Thorax</source>
<year>2003</year>; <volume>58</volume>: <fpage>339</fpage>&#x02013;<lpage>343</lpage><pub-id pub-id-type="pmid">12668799</pub-id></mixed-citation></ref><ref id="b12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Albert</surname><given-names>RK</given-names></name><name><surname>Connett</surname><given-names>J</given-names></name><name><surname>Bailey</surname><given-names>WC</given-names></name><etal/></person-group>
<article-title>Azithromycin for prevention of exacerbations of COPD</article-title>. <source>N Engl J Med</source>
<year>2011</year>; <volume>365</volume>: <fpage>689</fpage>&#x02013;<lpage>698</lpage><pub-id pub-id-type="pmid">21864166</pub-id></mixed-citation></ref><ref id="b13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamaya</surname><given-names>M</given-names></name><name><surname>Azuma</surname><given-names>A</given-names></name><name><surname>Takizawa</surname><given-names>H</given-names></name><etal/></person-group>
<article-title>Macrolide effects on the prevention of COPD exacerbations</article-title>. <source>Eur Respir J</source>
<year>2012</year>; <volume>40</volume>: <fpage>485</fpage>&#x02013;<lpage>494</lpage><pub-id pub-id-type="pmid">22408201</pub-id></mixed-citation></ref></ref-list></back></article>